Colorectal cancer is next for VEGF bispecifics
Pumitamig is the latest to be tested in first-line disease.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
